---
title: "Barclays Reaffirms Their Buy Rating on MacroGenics (MGNX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286391219.md"
description: "Barclays analyst Etzer Darout has reaffirmed a Buy rating on MacroGenics (MGNX) with a price target of $6.00. The analyst focuses on the Healthcare sector and has an average return of 26.4% with a 56.04% success rate on stock recommendations. The current consensus on MacroGenics is a Moderate Buy, with an average price target of $6.33."
datetime: "2026-05-14T09:25:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286391219.md)
  - [en](https://longbridge.com/en/news/286391219.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286391219.md)
---

# Barclays Reaffirms Their Buy Rating on MacroGenics (MGNX)

In a report released today, Etzer Darout from Barclays maintained a Buy rating on MacroGenics, with a price target of $6.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Darout covers the Healthcare sector, focusing on stocks such as Incyte, Legend Biotech, and Oruka Therapeutics. According to TipRanks, Darout has an average return of 26.4% and a 56.04% success rate on recommended stocks.

Currently, the analyst consensus on MacroGenics is a Moderate Buy with an average price target of $6.33.

### Related Stocks

- [MGNX.US](https://longbridge.com/en/quote/MGNX.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)
- [ORKA.US](https://longbridge.com/en/quote/ORKA.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [MacroGenics Q1 revenue rises, beats estimates on client production and cancer drug royalties](https://longbridge.com/en/news/286310410.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)